Investors

Date	Name	Title	Type	Shares Traded	Price Range
Feb 14, 2012	goldstein joseph l	Director	Automatic Sell	15,000	110.02
Feb 14, 2012	goldstein joseph l	Director	Option Execute	15,000	24.41 - 33.42
Mar 9, 2011	goldstein joseph l	Director	Option Execute	15,000	9.17
Jul 25, 2012	powchik peter	Officer	Option Execute	15,000	16.80
Sep 18, 2012	powchik peter	Officer	Option Execute	15,000	16.80
Aug 23, 2012	roberts william	Officer	Automatic Sell	15,000	144.00
Jan 18, 2011	shooter eric m	Director	Automatic Sell	15,000	35.00
Jan 18, 2011	shooter eric m	Director	Option Execute	15,000	19.69 - 23.84
Feb 17, 2010	shooter eric m	Director	Automatic Sell	15,000	30.00
Feb 17, 2010	shooter eric m	Director	Option Execute	15,000	18.80
Jan 5, 2010	shooter eric m	Director	Automatic Sell	15,000	25.00
Jan 5, 2010	shooter eric m	Director	Option Execute	15,000	15.01
Jan 21, 2010	shooter eric m	Director	Automatic Sell	15,000	26.00
Jan 21, 2010	shooter eric m	Director	Option Execute	15,000	15.80
May 30, 2008	shooter eric m	Director	Sell	15,000	19.80 - 19.88
May 30, 2008	shooter eric m	Director	Option Execute	15,000	9.17
Nov 22, 2011	sing george l	Director	Option Execute	15,000	28.81
Aug 1, 2012	powchik peter	Officer	Option Execute	14,990	15.64 - 21.92
Apr 3, 2009	vagelos p roy	Director	Disposition (Non Open Market)	14,976	n/a
Feb 17, 2011	goldberg murray a	Officer	Option Execute	14,850	19.43
Showing 221-240 of 638 transactions Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  See Previous 20 | See Next 20

Stock transaction information provided by EDGAR Online. Regeneron Pharmaceuticals, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.